El-Gazzaz G, Wong W, El-Hadary M K, Gunson B K, Mirza D F, Mayer A D, Buckels J A, McMaster P
Liver Unit, Queen Elizabeth Hospital, Birmingham, UK.
Transpl Int. 2000;13 Suppl 1:S406-9. doi: 10.1007/s001470050372.
Fibrolamellar hepatocellular carcinoma (FL HCC) is an uncommon variant of hepatocellular carcinoma occurring usually in non-cirrhotic livers. Hepatic resection or transplantation offers the only chance of cure. We reviewed our experience of surgery for FL HCC from 1985-1998. Twenty patients with FL HCC (13 females and 7 males) median age 27 years (range 12-69) were treated either by hepatic resection [n = 11; extended right hepatectomy (5), extended left hepatectomy (1), right hemihepatectomy (2), left hemihepatectomy (2), left lateral segmentectomy (1)] or, if the disease was non-resectable, by transplantation (n = 9). The median follow up was 25 months (1-63). The prognostic factors analysed included size [less than 5 cm (3 patients), more than 5 cm (17 patients)], number [solitary (16 patients), multiple (4 patients)], capsular invasion (6 patients), vascular invasion (11 patients) and lymph node invasion (6 patients). The overall survival at 1, 3 and 5 years was 89.5, 75 and 50%, respectively. The liver resection survival was better than liver transplantation survival at 3 years 100 vs 76%, respectively (P < 0.025). Although all prognostic factors analysed did not show a significant difference, there is tendency that tumour stage was the most significant for prognosis. Most of the patients in this study are young and presented without specific symptoms, with normal liver function range and had no tumour marker to help in diagnosis. As a result most of our patients were diagnosed late. However the outcome of surgical intervention was favourable.
纤维板层型肝细胞癌(FL HCC)是肝细胞癌的一种罕见变异类型,通常发生于非肝硬化肝脏。肝切除或肝移植是唯一的治愈机会。我们回顾了1985年至1998年期间FL HCC的手术治疗经验。20例FL HCC患者(13例女性,7例男性),中位年龄27岁(范围12 - 69岁),接受了肝切除治疗(n = 11;扩大右肝切除术(5例)、扩大左肝切除术(1例)、右半肝切除术(2例)、左半肝切除术(2例)、左外侧段切除术(1例)),如果疾病不可切除,则接受肝移植治疗(n = 9)。中位随访时间为25个月(1 - 63个月)。分析的预后因素包括肿瘤大小[小于5 cm(3例患者)、大于5 cm(17例患者)]、数量[单发(16例患者)、多发(4例患者)]、包膜侵犯(6例患者)、血管侵犯(11例患者)和淋巴结侵犯(6例患者)。1年、3年和5年的总生存率分别为89.5%、75%和50%。肝切除术后3年生存率优于肝移植术后生存率,分别为100%和76%(P < 0.025)。虽然分析的所有预后因素均未显示出显著差异,但肿瘤分期对预后的影响有增大趋势。本研究中的大多数患者较为年轻,就诊时无特异性症状,肝功能正常范围,且无肿瘤标志物辅助诊断。因此,我们的大多数患者诊断较晚。然而,手术干预的结果是良好的。